Tradestie Institutional Equity Comparison Engine

ELTX vs URGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

URGN Overall Edge

URGN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to UroGen Pharma Ltd. Ordinary Shares (URGN) driven by superior Valuation, Momentum & Technical, Options & Structure while ELTX counters with relative strength in Growth & Margin. Fundamentally, ELTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus URGN at 11.1x Forward P/E and -12.4% operating margin (+223.9% YoY). In options structure, ELTX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against URGN sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner URGN
ELTX N/M vs URGN 11.1x Fwd P/E
Growth & Margin Winner ELTX
Op Margin 0.0% vs -12.4% ยท YoY +0.0% vs +223.9%
Momentum & Technical Winner URGN
1Y -82.1% vs +9.4% ยท 52W Pos 1% vs 32%
Options & Structure Winner URGN
UNCLASSIFIED (<1st %ile IV) vs CONSOLIDATION (10th %ile IV)
ELTX NASDAQ
Elicio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-3.33% 1D
Market Cap $42.5M
1M Return -25.26%
1Y Return -82.1%
Forward P/E N/M
Unified AI Score
53.1 / 100 HOLD
Tech 72.0 Fund 60.0 Flow 66.0 Mom 54.0
URGN NASDAQ
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$27.65
-12.86% 1D
Market Cap $1.5B
1M Return -21.34%
1Y Return +9.42%
Forward P/E 11.1x
Unified AI Score
62.7 / 100 BUY
Tech 58.0 Fund 59.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELTX -82.1% URGN +9.42% Spread: +91.52 pp (URGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ELTX Revenue URGN Revenue ELTX Op. Margin URGN Op. Margin Margin Edge
FY2018 N/A $0M N/A -6842.2% URGN
FY2019 N/A $0M N/A -608211.1% URGN
FY2020 $0M $10M -1919.2% -1074.2% URGN
FY2021 $30M $50M -138.8% -192.1% ELTX
FY2022 $0M $60M -1031.4% -122.8% URGN
FY2023 N/A $80M N/A -79.2% URGN
FY2024 N/A $90M N/A -107.1% URGN
FY2025 N/A $110M N/A -113.7% URGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELTX (3) vs URGN (7)
Institutional Metric ELTX URGN Criterion Row Winner
Market Capitalization Scale $42.5M $1.5B Larger Scale URGN
Trailing P/E Ratio Valuation N/M 14.6x Lower Multiple URGN
Forward P/E Ratio Valuation N/M 11.1x Lower Multiple URGN
Revenue Growth (YoY) Growth +0.0% +223.9% Higher Growth URGN
Operating Margin (TTM) Profitability 0.0% -12.4% Higher Margin ELTX
Net Profit Margin Profitability 0.0% -26.3% Higher Margin ELTX
Return on Equity (ROE) Capital Efficiency -315.3% -1481.3% Higher ROE ELTX
52-Week Range Position Momentum 1% ($1โ€“$16) 32% ($16โ€“$51) Stronger Trend URGN
Beta / 30D Volatility Risk Regime 0.41ฮฒ ยท 92% Vol 1.24ฮฒ ยท 90% Vol Lower Realized Risk URGN
Unified Institutional Score Composite Signal 53.1 / 100 (HOLD) 62.7 / 100 (BUY) Higher Composite URGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELTX vs URGN Buy Guide
ELTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ELTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
URGN CONSOLIDATION
100d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live URGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELTX nor URGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.